Targeting IκB proteins for HIV latency activation: The role of individual IκB and NF-κB proteins

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3966-3978

  Fernandez, Guerau ^a,e   Zaikos, Thomas D ^b,f   Khan, Sohrab Z ^a   Jacobi, Ashley M ^c   Behlke, Mark A ^c   Zeichner, Steven L ^a,d  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c INTEGRATED DNA TECHNOLOGIES   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e Institut de Medicina Predictiva I Personalitzada del Càncer Ctra de Can Ruti   (Spain)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; SMALL INTERFERING RNA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINEAGE; CELL STRAIN; CELL STRAIN J LAT 10.6; CELL STRAIN U1; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KINETICS; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; T LYMPHOCYTE; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS REACTIVATION;

CELL LINE, TUMOR; DIMERIZATION; GENE KNOCKDOWN TECHNIQUES; HIV-1; HUMANS; HYDROXAMIC ACIDS; I-KAPPA B PROTEINS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LINEAR MODELS; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA; VIRUS LATENCY;

MAMMALIA;

EID: 84875549556     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03251-12     Document Type: Article

References (81)

1. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, Wong JK. 2003. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 77:11212-11219.
2. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea AM, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS. 2005. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250-3255.
3. Bisgrove D, Lewinski M, Bushman F, Verdin E. 2005. Molecular mechanisms of HIV-1 proviral latency. Expert Rev. Anti Infect. Ther. 3:805-814.
4. Shen L, Siliciano RF. 2008. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 122:22-28.
5. Geeraert L, Kraus G, Pomerantz RJ. 2008. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu. Rev. Med. 59:487-501.
6. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-8873.
7. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
8. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
9. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
10. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
11. Hamer DH. 2004. Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr. HIV Res. 2:99-111.
12. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. 2009. The challenge of finding a cure for HIV infection. Science 323:1304-1307.
13. Marsden MD, Zack JA. 2009. Eradication of HIV: current challenges and new directions. J. Antimicrob. Chemother. 63:7-10.
14. Mbonye U, Karn J. 2011. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr. HIV Res. 9:554-567.
15. Pion M, Jordan A, Biancotto A, Dequiedt F, Gondois-Rey F, Rondeau S, Vigne R, Hejnar J, Verdin E, Hirsch I. 2003. Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J. Virol. 77:4025-4032.
16. Van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15:1112-1120.
17. Matalon S, Rasmussen TA, Dinarello CA. 2011. Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17:466-472.
18. Laughlin M, Zeichner S, Kolson D, Alwine J, Seshamma T, Pomerantz R, Gonzalez-Scaran F. 1993. Sodium butyrate treatment of cells latently infected with HIV-1 results in the expression of unspliced viral RNA. Virology 196:496-505.
19. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18:1101-1108.
20. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. 2009. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25: 207-212.
21. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. 2009. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J. Biol. Chem. 284:6782-6789.
22. Fernandez G, Zeichner SL. 2010. Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol. J. 7:266. doi:10.1186/1743-422X-7-266.
23. Krishnan V, Zeichner SL. 2004. Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency. J. Virol. 78:9458-9473.
24. Tyagi M, Karn J. 2007. CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 26:4985-4995.
25. Zhang Z, Klatt A, Henderson AJ, Gilmour DS. 2007. Transcription termination factor Pcf11 limits the processivity of Pol II on an HIV provirus to repress gene expression. Genes Dev. 21:1609-1614.
26. du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A, Emiliani S, Kiernan R, Benkirane M. 2007. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26:424-435.
27. Nabel G, Baltimore D. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326:711-713. (Erratum, 344:178, 1990.)
28. Jones KA, Kadonaga JT, Luciw PA, Tjian R. 1986. Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. Science 232: 755-759.
29. Perkins ND, Edwards NL, Duckett CS, Agranoff AB, Schmid RM, Nabel GJ. 1993. A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation. EMBO J. 12:3551-3558.
30. El Kharroubi A, Piras G, Zensen R, Martin MA. 1998. Transcriptionalactivation of the integrated chromatin-associated human immunodeficiency virus type 1 promoter. Mol. Cell. Biol. 18:2535-2544.
31. Berkhout B, Jeang KT. 1992. Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J. Virol. 66:139-149.
32. Kaufman JD, Valandra G, Roderiquez G, Bushar G, Giri C, Norcross MA. 1987. Phorbol ester enhances human immunodeficiency viruspromoted gene expression and acts on a repeated 10-base-pair functional enhancer element. Mol. Cell. Biol. 7:3759-3766.
33. Zeichner SL, Kim JY, Alwine JC. 1991. Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeat. J. Virol. 65:2436-2444.
34. Tong-Starksen SE, Luciw PA, Peterlin BM. 1987. Human immunodeficiency virus long terminal repeat responds to T-cell activation signals. Proc. Natl. Acad. Sci. U. S. A. 84:6845-6849.
35. Kinoshita S, Su L, Amano M, Timmerman LA, Kaneshima H, Nolan GP. 1997. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 6:235-244.
36. Zeichner SL, Hirka G, Andrews PW, Alwine JC. 1992. Differentiationdependent human immunodeficiency virus long terminal repeat regulatory elements active in human teratocarcinoma cells. J. Virol. 66:2268-2273.
37. Basseres DS, Baldwin AS. 2006. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830.
38. Hayden MS, Ghosh S. 2008. Shared principles in NF-kappaB signaling. Cell 132:344-362.
39. Gilmore TD. 2006. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25:6680-6684.
40. Hoffmann A, Leung TH, Baltimore D. 2003. Genetic analysis of NFkappaB/ Rel transcription factors defines functional specificities. EMBO J. 22:5530-5539.
41. Natoli G, Saccani S, Bosisio D, Marazzi I. 2005. Interactions of NFkappaB with chromatin: the art of being at the right place at the right time. Nat. Immunol. 6:439-445.
42. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. 2006. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-149.
43. Williams SA, Greene WC. 2007. Regulation of HIV-1 latency by T-cell activation. Cytokine 39:63-74.
44. Williams SA, Kwon H, Chen LF, Greene WC. 2007. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J. Virol. 81:6043-6056.
45. Rohr O, Marban C, Aunis D, Schaeffer E. 2003. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J. Leukoc. Biol. 74:736-749.
46. Stellbrink HJ, Hufert FT, Tenner-Racz K, Lauer J, Schneider C, Albrecht H, Racz P, van Lunzen J. 1998. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2. Antivir. Ther. 3:209-214.
47. Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, Herpin B, Perry C, Hallahan CW, Davey RT, Metcalf JA, Connors M, Fauci AS. 2002. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J. Infect. Dis. 185: 61-68.
48. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, Davey RT, Jr, Dybul M, Kovacs JA, Metcalf JA, Mican JM, Berrey MM, Corey L, Lane HC, Fauci AS. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655.
49. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, ten Berge IJ, Yong SL, Fox CH, Roos MT, de Wolf F, Goudsmit J, Schuitemaker H, Lange JM. 1999. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13:2405-2410.
50. Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, Greene WC. 2004. Prostratin antagonizes HIV latency by activating NFkappaB. J. Biol. Chem. 279:42008-42017.
51. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA. 2002. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 76:8118-8123.
52. Hoffmann A, Natoli G, Ghosh G. 2006. Transcriptional regulation via the NF-kappaB signaling module. Oncogene 25:6706-6716.
53. Baltathakis I, Alcantara O, Boldt DH. 2001. Expression of different NF-kappaB pathway genes in dendritic cells (DCs) or macrophages assessed by gene expression profiling. J. Cell. Biochem. 83:281-290.
54. Griffin BD, Moynagh PN. 2006. In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation. Biochem. J. 400:115-125.
55. Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. 2006. Ikappa-Bepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. J. Cell Biol. 173: 659-664.
56. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB, White MR. 2004. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306:704-708.
57. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W, Banerjee A. 2006. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 25:6781-6799.
58. Pasparakis M, Luedde T, Schmidt-Supprian M. 2006. Dissection of the NF-kappaB signalling cascade in transgenic and knockout mice. Cell Death Differ. 13:861-872.
59. Klement JF, Rice NR, Car BD, Abbondanzo SJ, Powers GD, Bhatt PH, Chen CH, Rosen CA, Stewart CL. 1996. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol. Cell. Biol. 16:2341-2349.
60. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P, Ghosh S. 1995. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 80:573-582.
61. Whiteside ST, Epinat JC, Rice NR, Israel A. 1997. I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J. 16:1413-1426.
62. Li Z, Nabel GJ. 1997. A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol. Cell. Biol. 17:6184-6190.
63. Memet S, Laouini D, Epinat JC, Whiteside ST, Goudeau B, Philpott D, Kayal S, Sansonetti PJ, Berche P, Kanellopoulos J, Israel A. 1999. IkappaBepsilon-deficient mice: reduction of one T cell precursor subspecies and enhanced Ig isotype switching and cytokine synthesis. J. Immunol. 163:5994-6005.
64. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800-802.
65. Jordan A, Bisgrove D, Verdin E. 2003. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22:1868-1877.
66. Colin L, Van Lint C. 2009. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6:111. doi:10.1186/1742-4690-6-111.
67. Le Douce V, Janossy A, Hallay H, Ali S, Riclet R, Rohr O, Schwartz C. 2012. Achieving a cure for HIV infection: do we have reasons to be optimistic? J. Antimicrob. Chemother. 67:1063-1074.
68. Marsden MD, Zack JA. 2010. Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virol. 5:97-109.
69. Malek S, Chen Y, Huxford T, Ghosh G. 2001. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. J. Biol. Chem. 276:45225-45235.
70. Tam WF, Sen R. 2001. IkappaB family members function by different mechanisms. J. Biol. Chem. 276:7701-7704.
71. Kanarek N, Ben-Neriah Y. 2012. Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol. Rev. 246:77-94.
72. Tran K, Merika M, Thanos D. 1997. Distinct functional properties of IkappaB alpha and IkappaB beta. Mol. Cell. Biol. 17:5386-5399.
73. McNamara LA, Ganesh JA, Collins KL. 2012. Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation. J. Virol. 86:9337-9350.
74. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC.2012. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One 7:e30176. doi:10.1371/journal .pone.0030176.
75. + cells is due to epigenetic transcriptional silencing and PTEFb restriction. J. Virol. 84:6425-6437.
76. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF. 2009. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119:3473-3486.
77. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P. 2008. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134:577-586.
78. Kim SS, Subramanya S, Peer D, Shimaoka M, Shankar P. 2011. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol. Biol. 721:339-353.
79. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, Seung E, Deruaz M, Dudek T, Einarsson JI, Yang L, Allen TM, Luster AD, Tager AM, Dykxhoorn DM, Lieberman J. 2011. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Invest. 121:2401-2412.
80. de Fougerolles AR. 2008. Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 19:125-132.
81. Peer D, Lieberman J. 2011. Special delivery: targeted therapy with small RNAs. Gene Ther. 18:1127-1133.